SCHEMBL6505437

SCHEMBL6505437

[CH2]NC(=O)c1c(OC)cccc1OC

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.55
TSHR P16473 1/20 0.55
MAPT P10636 1/20 0.54
KMT2A Q03164 1/20 0.54
TAAR1 Q96RJ0 1/20 0.54
ATM Q13315 1/20 0.54
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156158 0.83 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL11263913 0.83 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL27842201 0.82 CTSD (0.65) CA12CA1CA2CA7CA9
SCHEMBL26334167 0.82 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL13527523 0.82 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL13761306 0.80 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL6504497 0.80 CTSD (0.68) SMN1; SMN2TSHRMAPTTP53ALDH1A1
SCHEMBL4155014 0.79 TAAR1 (0.62) CA12CA1CA2CA7CA9
SCHEMBL27675554 0.79 KMT2A (0.58) CA12CA1CA2CA7CA9
SCHEMBL19531887 0.79 CA12 (0.55) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO claimed
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO disclosed